A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)

被引：1
|
作者：
Cascinu, S. [1 ]
Lonardi, S. [2 ]
Rosati, G. [3 ]
Nasti, G. [4 ]
Zaniboni, A. [5 ]
Romiti, A. [6 ]
Aglietta, M. [7 ]
Bilancia, D.
Iaffaioli, V. [4 ]
Zagonel, V. [2 ]
Giordano, M. [8 ]
Corsi, D. [9 ]
Ferrau, F. [10 ]
Labianca, R. [11 ]
Berardi, R. [12 ]
Rulli, E. [13 ]
Floriani, I. [13 ]
机构：
[1] Azienda Osped Reg Torrette, Clin Oncol Med, Ancona, Italy
[2] Ist Oncol Veneto, UO Oncol Med, Padua, Italy
[3] Azienda Osped S Carlo, UO Oncol Med, Potenza, Italy
[4] INT IRCCS Fdn Pascale, UO Oncol Med, Naples, Italy
[5] Fdn Poliambulanza, UO Oncol Med, Brescia, Italy
[6] AOU Policlin St Andrea, UO Oncol Med, Rome, Italy
[7] Ist Candiolo IRCCS, UO Oncol Med, Candiolo, TO, Italy
[8] Osped St Anna, UO Oncol Med, Como, Italy
[9] Osped San Pietro Fatebenefratelli, UO Oncol Med, Rome, Italy
[10] Osped San Vincenzo, UO Oncol Med, Taormina, Italy
[11] Osped Papa Giovanni XXIII, UO Oncol Med, Bergamo, Italy
[12] Azienda Osped Reginale Torrette, Clin Oncol Med, Ancona, Italy
[13] Ist Ric Farmacol Mario Negri, Lab Ric Clin, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(15)30040-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [31] Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
    Hamidou, Zeinab
    Chibaudel, Benoist
    Hebbar, Mohamed
    de Larauze, Marine Hug
    Andre, Thierry
    Louvet, Christophe
    Brusquant, David
    Garcia-Larnicol, Marie-Line
    de Gramont, Aimery
    Bonnetain, Franck
    PLOS ONE, 2016, 11 (06):
  • [32] FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
    Hebbar, M.
    Chibaudel, B.
    Andre, T.
    Mineur, L.
    Smith, D.
    Louvet, C.
    Dutel, J. L.
    Ychou, M.
    Legoux, J. L.
    Mabro, M.
    Faroux, R.
    Auby, D.
    Brusquant, D.
    Khalil, A.
    Truant, S.
    Hadengue, A.
    Dalban, C.
    Gayet, B.
    Paye, F.
    Pruvot, F. R.
    Bonnetain, F.
    Taieb, J.
    Brucker, P.
    Landi, B.
    Flesch, M.
    Carola, E.
    Martin, P.
    Vaillant, E.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 340 - 347
  • [33] Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
    Xu, Rui-Hua
    Muro, Kei
    Morita, Satoshi
    Iwasa, Satoru
    Han, Sae Won
    Wang, Wei
    Kotaka, Masahito
    Nakamura, Masato
    Ahn, Joong Bae
    Deng, Yan-Hong
    Kato, Takeshi
    Cho, Sang-Hee
    Ba, Yi
    Matsuoka, Hiroshi
    Lee, Keun-Wook
    Zhang, Tao
    Yamada, Yasuhide
    Sakamoto, Junichi
    Park, Young Suk
    Kim, Tae Won
    LANCET ONCOLOGY, 2018, 19 (05): : 660 - 671
  • [35] Impact of primary tumour side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase III TAILOR trial
    Qin, S.
    Liu, T.
    Xu, J.
    Li, Q.
    Cheng, Y.
    Nippgen, J.
    Chen, W.
    Li, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [37] Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
    Aparicio, J.
    Virgili Manrique, A. C.
    Capdevila, J.
    Munoz Boza, F.
    Galvan, P.
    Richart, P.
    Oliveres, H.
    Paez, D.
    Hernando, J.
    Garcia Serrano, S.
    Vera, R.
    Hernandez, X.
    Alvarez Gallego, R.
    Riesco-Martinez, M. C.
    Garcia de Albeniz, X.
    Maurel, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S543 - S543
  • [38] Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.
    Qin, Shukui
    Guo, Weijian
    Xu, Jian-Ming
    Li, Qi
    Cheng, Ying
    Liu, Tian Shu
    Chen, Jiongjie
    Chen, Wen-Feng
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial
    Qin, S.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Liu, T.
    Chen, J.
    Eggleton, S. P.
    Liu, J.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Sequential treatment strategy for metastatic colorectal cancer: A phase III study of chemotherapy (CT) with or without bevacizumab (Bev) as first-line therapy followed by two phase III studies of CT alone or CT plus bev with or without cetuximab (Cetux) as second-line therapy (ITACa Study IRST 153 01).
    Fabbri, F.
    Passardi, A.
    Ravaioli, A.
    Cavanna, L.
    Luppi, G.
    Mucciarini, C.
    Faedi, M.
    Turci, D.
    Pasquini, E.
    Vertogen, B.
    Milandri, C.
    Amadori, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345